A simple modification converts an electrospray ion source to an ambient-pressure helium plasma ionization source without the need of additional expensive hardwa
Otamixaban is a potent (Ki ? 0.5 nM) fXa inhibitor currently in late-stage clinical develop-ment at Sanofi for the management of acute coronary syndrome. Being